Eckert & Ziegler Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
1,100
- Stock Symbol
-
EUZ
- Investments
-
36
- Share Price
-
$15.88
- (As of Friday Closing)
Eckert & Ziegler General Information
Description
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
Contact Information
Website
www.ezag.comCorporate Office
- Robert-Rössle-Street.10
- 13125 Berlin
- Germany
Corporate Office
- Robert-Rössle-Street.10
- 13125 Berlin
- Germany
Eckert & Ziegler Stock Performance
As of 20-Nov-2026, Eckert & Ziegler’s stock price is $15.88. Its current market cap is $994M with 62.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.88 | $16.18 | $13.40 - $19.62 | $994M | 62.6M | 107K | $1.01 |
Eckert & Ziegler Financials Summary
As of 30-Sep-2026, Eckert & Ziegler has a trailing 12-month revenue of $368M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 827,016 | 1,038,129 | 921,624 | 925,378 |
| Revenue | 368,086 | 351,893 | 320,139 | 266,290 |
| EBITDA | 111,251 | 102,441 | 85,274 | 63,655 |
| Net Income | 63,144 | 55,005 | 36,008 | 28,459 |
| Total Assets | 563,121 | 537,889 | 460,345 | 485,673 |
| Total Debt | 43,850 | 52,629 | 57,584 | 62,238 |
Eckert & Ziegler Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Eckert & Ziegler Comparisons
Industry
Financing
Details
Eckert & Ziegler Competitors (8)
One of Eckert & Ziegler’s 8 competitors is Bio-Rad Laboratories, a Corporation company based in Hercules, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
| Bruker | Formerly VC-backed | Billerica, MA | ||||
| W. L. Gore and Associates | Private Debt Financed | Newark, DE | ||||
| Ion Beam Applications | Corporation | Louvain-La-Neuve, Belgium | ||||
| Guerbet Group | Corporation | Villepinte, France |
Eckert & Ziegler Patents
Eckert & Ziegler Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2543412-A1 | Emitter points module for an afterloader and afterloader system with afterloader and emitter points module | Inactive | 05-Jul-2011 | ||
| ES-2375927-T3 | Apparatus and system for combining links that include radioactive sources until forming a chain. | Active | 12-Feb-2010 | ||
| EP-2359904-A1 | Cartridge for chain components of a chain with radioactive radiation sources and a system comprising a chain component and a cartridge | Active | 12-Feb-2010 | ||
| EP-2359904-B1 | Cartridge for chain components of a chain with radioactive radiation sources and a system comprising a chain component and a cartridge | Inactive | 12-Feb-2010 | ||
| JP-2011161237-A | Device and system for assembling chain component to form chain | Pending | 12-Feb-2010 | A61N5/1001 |
Eckert & Ziegler Signals
Eckert & Ziegler Investments & Acquisitions (36)
Eckert & Ziegler’s most recent deal was a Joint Venture with Radioisotopes Production (Eckert & Ziegler Strahlen- und Medizintechnik / DC Pharma) for . The deal was made on 14-Nov-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Radioisotopes Production (Eckert & Ziegler Strahlen- und Medizintechnik / DC Pharma) | 14-Nov-2023 | Joint Venture | Other Energy | ||
| Myelo Therapeutics | 15-Dec-2022 | Merger/Acquisition | Drug Discovery | ||
| Pentixapharm | 16-Apr-2021 | Merger/Acquisition | Drug Discovery | ||
| Qikangyuan | 15-Apr-2021 | Joint Venture | Pharmaceuticals | ||
| Myelo Therapeutics | 26-Jun-2020 | Later Stage VC | Drug Discovery |
Eckert & Ziegler ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
28.76 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Eckert & Ziegler Exits (5)
Eckert & Ziegler’s most recent exit was on 16-Apr-2021 from Pentixapharm. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Pentixapharm | 16-Apr-2021 | Completed |
|
||
| TCL Eckert & Ziegler BEBIG Healthcare | 01-Aug-2019 | Completed |
|
||
| Curasight | 01-Feb-2016 | Completed |
|
||
| OctreoPharm Sciences | 22-Jul-2013 | Completed |
|
||
| Analytics (Minnesota) | 11-Aug-2005 | Merger/Acquisition | Completed |
Eckert & Ziegler Affiliates
Subsidiaries (6)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Myelo Therapeutics | Berlin, Germany | 2013 | |
| nuclitec | Brunswick, Germany | 1998 | |
| Gamma-Service Recycling | Leipzig, Germany | 1998 | |
| Eckert & Ziegler f-con Europe | Berlin, Germany | 1995 | |
| Eckert & Ziegler Chemotrade | Dusseldorf, Germany | 1992 |
Eckert & Ziegler FAQs
-
When was Eckert & Ziegler founded?
Eckert & Ziegler was founded in 1997.
-
Where is Eckert & Ziegler headquartered?
Eckert & Ziegler is headquartered in Berlin, Germany.
-
What is the size of Eckert & Ziegler?
Eckert & Ziegler has 1,100 total employees.
-
What industry is Eckert & Ziegler in?
Eckert & Ziegler’s primary industry is Diagnostic Equipment.
-
Is Eckert & Ziegler a private or public company?
Eckert & Ziegler is a Public company.
-
What is Eckert & Ziegler’s stock symbol?
The ticker symbol for Eckert & Ziegler is EUZ.
-
What is the current stock price of Eckert & Ziegler?
As of 20-Nov-2026 the stock price of Eckert & Ziegler is $15.88.
-
What is the current market cap of Eckert & Ziegler?
The current market capitalization of Eckert & Ziegler is $994M.
-
What is Eckert & Ziegler’s current revenue?
The trailing twelve month revenue for Eckert & Ziegler is $368M.
-
Who are Eckert & Ziegler’s competitors?
Bio-Rad Laboratories, Bruker, W. L. Gore and Associates, Ion Beam Applications, and Guerbet Group are some of the 8 competitors of Eckert & Ziegler.
-
What is Eckert & Ziegler’s annual earnings per share (EPS)?
Eckert & Ziegler’s EPS for 12 months was $1.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process